Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura

Am J Hematol. 2018 Mar;93(3):E77-E79. doi: 10.1002/ajh.25007. Epub 2018 Jan 10.

Authors

Jennifer Ding¹, Maria R Baer¹, John R Hess², Ann B Zimrin¹

Affiliations

¹ Division of Hematology-Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, Maryland.
² Department of Laboratory Medicine, University of Washington, Seattle, Washington.

PMID: 29247542
DOI: 10.1002/ajh.25007

No abstract available

Publication types

Letter

MeSH terms

Adult
Combined Modality Therapy
Cyclosporine / therapeutic use
Drug Therapy, Combination
Female
Humans
Immunoglobulins, Intravenous / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic / drug therapy*
Purpura, Thrombotic Thrombocytopenic / therapy
Recurrence
Registries
Retrospective Studies
Salvage Therapy*
Splenectomy
Treatment Outcome
Vidarabine / analogs & derivatives
Vidarabine / therapeutic use
Vincristine / therapeutic use
Young Adult

Substances

Immunoglobulins, Intravenous
Immunosuppressive Agents
Vincristine
Cyclosporine
Vidarabine
fludarabine